Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice.
To investigate the effects of abolished cholic acid (CA) synthesis in the ApoE knockout model [apolipoprotein E (apoE) KO],a double-knockout (DKO) mouse model was created by crossbreeding Cyp8b1 knockout mice (Cyp8b1 KO), unable to synthesize the primary bile acid CA, with apoE KO mice. After 5 months of cholesterol feeding, the development of atherosclerotic plaques in the proximal aorta was 50% less in the DKO mice compared with the apoE KO mice. This effect was associated with reduced intestinal cholesterol absorption, decreased levels of apoB-containing lipoproteins in the plasma, enhanced bile acid synthesis, reduced hepatic cholesteryl esters, and decreased hepatic activity of ACAT2. The upregulation of Cyp7a1 in DKO mice seemed primarily caused by reduced expression of the intestinal peptide FGF15. Treatment of DKO mice with the farnesoid X receptor (FXR) agonist GW4064 did not alter the intestinal cholesterol absorption, suggesting that the action of CA in this process is confined mainly to formation of intraluminal micelles and less to its ability to activate the nuclear receptor FXR. Inhibition of CA synthesis may offer a therapeutic strategy for the treatment of hyperlipidemic conditions that lead to atherosclerosis.
Slätis
Katharina
K
Unit for Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Gåfvels
Mats
M
Kannisto
Kristina
K
Ovchinnikova
Olga
O
Paulsson-Berne
Gabrielle
G
Parini
Paolo
P
Jiang
Zhao-Yan
ZY
Eggertsen
Gösta
G
D000818:Animals; D001057:Apolipoproteins E / Q000097:blood / Q000172:deficiency* / Q000235:genetics*; D050197:Atherosclerosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D001646:Bile / Q000737:chemistry / Q000187:drug effects; D002784:Cholesterol / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism; D002793:Cholic Acids / Q000096:biosynthesis* / Q000172:deficiency* / Q000378:metabolism; D055786:Gene Knockout Techniques; D007408:Intestinal Absorption / Q000187:drug effects; D007555:Isoxazoles / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008823:Micelles; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000378:metabolism; D000099150:Receptor, Farnesoid X-Activated
D001057:Apolipoproteins E; D002784:Cholesterol; D002793:Cholic Acids; D007555:Isoxazoles; D008823:Micelles; D018160:Receptors, Cytoplasmic and Nuclear; D000099150:Receptor, Farnesoid X-Activated; C412815:GW 4064